Globus Medical/$GMED
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Globus Medical
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Ticker
$GMED
Sector
Primary listing
NYSE
Industry
Health Care Equipment and Supplies
Headquarters
Employees
5,300
Website
Globus Medical Metrics
BasicAdvanced
$7.2B
39.89
$1.34
1.20
-
Price and volume
Market cap
$7.2B
Beta
1.2
52-week high
$94.93
52-week low
$51.87
Average daily volume
1.5M
Financial strength
Current ratio
4.445
Quick ratio
2.598
Long term debt to equity
2.005
Total debt to equity
2.27
Interest coverage (TTM)
198.72%
Profitability
EBITDA (TTM)
720.966
Gross margin (TTM)
67.04%
Net profit margin (TTM)
7.39%
Operating margin (TTM)
18.16%
Effective tax rate (TTM)
20.34%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
5.90%
Return on equity (TTM)
4.63%
Valuation
Price to earnings (TTM)
39.891
Price to revenue (TTM)
2.888
Price to book
1.76
Price to tangible book (TTM)
3.83
Price to free cash flow (TTM)
14.01
Free cash flow yield (TTM)
7.14%
Free cash flow per share (TTM)
380.37%
Growth
Revenue change (TTM)
32.26%
Earnings per share change (TTM)
145.70%
3-year revenue growth (CAGR)
37.72%
10-year revenue growth (CAGR)
17.97%
3-year earnings per share growth (CAGR)
-0.87%
10-year earnings per share growth (CAGR)
2.84%
What the Analysts think about Globus Medical
Analyst ratings (Buy, Hold, Sell) for Globus Medical stock.
Bulls say / Bears say
Globus Medical reported a 60.6% increase in full-year 2024 net sales to $2.52 billion, driven by the successful integration of NuVasive and robust sales in spine products and enabling technologies. (biospace.com)
The company achieved a record operating cash flow of $520.6 million in 2024, providing flexibility for continued investment in innovation while maintaining financial discipline. (biospace.com)
Globus Medical reaffirmed its 2025 revenue guidance range of $2.66 billion to $2.69 billion, indicating confidence in sustained growth following the NuVasive merger. (biospace.com)
In Q1 2025, Globus Medical experienced a 1.4% decrease in worldwide net sales, primarily due to softer Enabling Technology deal closures and temporary supply chain disruptions. (santelog.com)
The company received an FDA warning letter regarding its ExcelsiusGPS robotic system, citing complaint handling and reporting deficiencies, which remains unresolved as of February 20, 2025. (panabee.com)
Globus Medical's cost of sales increased to 41% of net sales in 2024, up from 35% the previous year, driven by merger-related inventory amortization and elevated product expenses, potentially impacting gross margins. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Globus Medical Financial Performance
Revenues and expenses
Globus Medical Earnings Performance
Company profitability
Globus Medical News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Accesswire·1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Accesswire·1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Globus Medical stock?
Globus Medical (GMED) has a market cap of $7.2B as of July 25, 2025.
What is the P/E ratio for Globus Medical stock?
The price to earnings (P/E) ratio for Globus Medical (GMED) stock is 39.89 as of July 25, 2025.
Does Globus Medical stock pay dividends?
No, Globus Medical (GMED) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next Globus Medical dividend payment date?
Globus Medical (GMED) stock does not pay dividends to its shareholders.
What is the beta indicator for Globus Medical?
Globus Medical (GMED) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.